N/A N=22 Clinical Evaluation of the Treatment of Spider Angioma
Spider Angioma
Primary: Physician's Global Assessment Scale for Improvement of Spider Angioma — 4.5 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4 A Clinical Evaluation of the Treatment of Spider Veins on the Ankles
Spider Veins
Primary: Physician Global Assessment of Improvement in Treated Spider Veins on the Ankles — 3.7 score on a scale
N/A N=357 Hemangioma Associated With High Rates of Morbidity
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Phase 2 N=10 Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Lesion Area of Treated Telangiectasia. — -6; -8 mm^2
Phase 4 N=20 Treatment of Lower Extremity Spider Veins With Excel V
Telangiectasis · Spider Veins
Primary: Mean Improvement of Lower Extremity Spider Veins Based on Blinded Photo Assessments — 2.5 points on Improvement scale
N/A N=261 Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
Hemangioma
Primary: Frequency of Hepatic Hemangiomas Identified on Abdominal Ultrasound — 24 participants
N/A N=27 Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Port Wine Stain
Primary: Change From Baseline in a* and E at 8 Weeks — 1.27; 0.43; 4.08; 2.59 units on a scale
N/A N=15 Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata
Cherry Angioma
Primary: Mean Changes in Color, Texture, and Size of Cherry Angiomata From Baseline to 3 Months After the Second Treatment by Treatment Type as Assessed by Blinded Raters — 5.27…
Early Phase 1 N=14 Treating Arteriovenous Malformation With Stereotactic Radiosurgery Using CT Angiography for Treatment Planning
Arteriovenous Malformations
Primary: Target Volume Difference Between Standard of Care vs. CT Angiogram and MRI Alone — 1.1; 1.3 mL
Phase 4 N=115 Polidocanol Versus Glucose Treatment of Telangiectasia Trial
Varicose Veins · Telangiectasis
Primary: Change From Baseline in Extent of Telangiectasias — 57.24; 76.08 percent of change negative values
Phase 3 N=28 A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation
Hypervascular Tumor and Arteriovenous Malformation
Primary: Success Rate of Embolization in the Target Vessel — 100; 96.4 Percentage of participants
Phase 2 N=92 The Spot Sign for Predicting and Treating ICH Growth Study
Intracerebral Hemorrhage
Primary: Number of Study Subjects With Life-threatening Thromboembolic Complications — 1; 0; 0 Participants — p=1.00
Phase 2 N=32 Bevacizumab in Treating Patients With Angiosarcoma
Sarcoma
Primary: Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria. — 12.4 Weeks